FDA Expands Marketing Crackdown to Cancer Biologics, Targets Four Major Companies Over Misleading Survival Claims
核心洞察
The FDA's Center for Biologics Evaluation and Research issued untitled letters to four pharmaceutical companies on March 9, 2026, citing false or misleading promotional claims for cancer biologics including Bristol Myers Squibb (搜索)'s Breyanzi, Novartis' Kymriah, Gilead's Tecartus, and Iovance Biotherapeutics' Amtagvi.
The enforcement action specifically targeted promotional materials that referenced exploratory survival data such as overall survival and progression-free survival that went beyond the outcomes supporting regulatory approval for these CAR-T cell therapies.
This represents a significant expansion of the FDA's pharmaceutical marketing crackdown from direct-to-consumer advertising to direct-to-physician scientific marketing, with the agency warning that misleading claims could affect clinical decision-making and patient safety.
The FDA has significantly expanded its pharmaceutical marketing enforcement efforts, issuing warning letters to four major companies over misleading promotional claims for cancer biologics. On March 9, 2026, the FDA's Center for Biologics Evaluation and Research (CBER) sent untitled letters to Bristol Myers Squibb (搜索), Novartis, Gilead's Kite Pharma, and Iovance Biotherapeutics regarding false or misleading promotional materials for their respective cancer treatments.
Targeting Survival Data Claims Beyond Approved Indications
The enforcement action specifically focused on promotional materials that referenced "exploratory analyses" such as overall survival (OS) and progression-free survival (PFS) data that exceeded the scope of regulatory approval. The Iovance letter noted that marketing materials referenced OS data despite the company's Amtagvi being approved based on objective response rates. Similarly, Bristol Myers Squibb (搜索) and Novartis received letters addressing the presentation of survival outcomes not established as primary clinical benefits for their CAR-T cell therapies Breyanzi and Kymriah, respectively.
Gilead's Kite Pharma division faced scrutiny for materials referencing PFS, OS and relapse-free survival for Tecartus, while the product was approved based on response-based endpoints. The FDA emphasized that footnotes alone are insufficient to support compliance where the overall promotional message may be misleading.
Expansion of Pharmaceutical Marketing Crackdown
This enforcement action represents a notable expansion of the FDA's pharmaceutical marketing crackdown that began last fall. The latest letters from CBER signal the agency is broadening its scrutiny beyond direct-to-consumer marketing to include direct-to-physician scientific marketing materials and healthcare provider websites.
Before these March letters, CBER had issued only one warning letter to a biologic drugmaker since 2019—to AstraZeneca for a Flumist TV advertisement in 2025. Some biologics like AbbVie's Skyrizi and Novartis' Kesimpta were included in the FDA's initial enforcement sweep, but those letters focused on direct-to-consumer marketing rather than professional promotional materials.
Patient Safety Concerns Drive Enforcement
The FDA broadly stated in each letter that misleading promotional claims "may cause doctors and patients to inaccurately weigh the risks versus benefits of treatment... which can be fatal or life-threatening." This language underscores the agency's concern that promotional practices could affect clinical decision-making in oncology, where treatment choices carry significant implications for patient outcomes.
At least one company has responded publicly to the enforcement action. "We take patient safety and compliance seriously and are working to ensure our communications are accurate, balanced and consistent with the prescribing information," a Gilead spokesperson told Fierce Pharma.
Implications for Industry Marketing Practices
The enforcement letters signal that biologics and cancer drugs are clearly in the FDA's crosshairs, with potential implications for how aggressively companies promote some of their highest-value drugs. The scrutiny extends beyond traditional direct-to-consumer TV commercials and social media campaigns to include scientific marketing materials directed at healthcare providers.
For pharmaceutical marketers, these letters may indicate a continued rise in CBER enforcement activity following a historically quiet period. The action could push marketing, medical, and legal teams toward more conservative claims and longer campaign lead times as companies reassess their promotional strategies to ensure compliance with regulatory standards.